262 related articles for article (PubMed ID: 19302288)
1. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Ishikawa A; Ishikawa E; Otsuji M; Iizasa T; Hanaoka H; Shimizu N; Horiguchi S; Okamoto Y; Fujii S; Taniguchi M; Fujisawa T; Nakayama T
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6079-86. PubMed ID: 17028247
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
[TBL] [Abstract][Full Text] [Related]
4. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
[TBL] [Abstract][Full Text] [Related]
7. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
9. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ
Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
Nicol AJ; Tazbirkova A; Nieda M
Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
[TBL] [Abstract][Full Text] [Related]
12. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes.
Okada H; Nagamura-Inoue T; Mori Y; Takahashi TA
Eur J Immunol; 2006 Jan; 36(1):236-44. PubMed ID: 16380959
[TBL] [Abstract][Full Text] [Related]
13. The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients.
Konishi J; Yamazaki K; Yokouchi H; Shinagawa N; Iwabuchi K; Nishimura M
Hum Immunol; 2004 Nov; 65(11):1377-88. PubMed ID: 15556688
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
15. The effects of alphaGalCer-induced TCRValpha24 Vbeta11(+) natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
Ueda Y; Hagihara M; Gansuvd B; Yu Y; Masui A; Okamoto A; Higuchi A; Tazume K; Kato S; Hotta T
Cancer Immunol Immunother; 2003 Oct; 52(10):625-31. PubMed ID: 12802518
[TBL] [Abstract][Full Text] [Related]
16. Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.
Rogers PR; Matsumoto A; Naidenko O; Kronenberg M; Mikayama T; Kato S
J Immunol Methods; 2004 Feb; 285(2):197-214. PubMed ID: 14980434
[TBL] [Abstract][Full Text] [Related]
17. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells.
Imataki O; Heike Y; Makiyama H; Iizuka A; Ikarashi Y; Ishida T; Wakasugi H; Takaue Y
Cytotherapy; 2008; 10(5):497-506. PubMed ID: 18608348
[TBL] [Abstract][Full Text] [Related]
18. A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.
Okita K; Motohashi S; Shinnakasu R; Nagato K; Yamasaki K; Sato Y; Kitamura H; Hijikata A; Yamashita M; Shimizu K; Fujii S; Ohara O; Taniguchi M; Sakaida I; Nakayama T
Cancer Sci; 2010 Nov; 101(11):2333-40. PubMed ID: 20804502
[TBL] [Abstract][Full Text] [Related]
19. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin.
Gorbachev AV; Fairchild RL
Eur J Immunol; 2006 Sep; 36(9):2494-503. PubMed ID: 16909435
[TBL] [Abstract][Full Text] [Related]
20. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas.
Tachibana T; Onodera H; Tsuruyama T; Mori A; Nagayama S; Hiai H; Imamura M
Clin Cancer Res; 2005 Oct; 11(20):7322-7. PubMed ID: 16243803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]